Factbox-Major deals involving US drugmakers and biotechs over the past decade
Overview of Major US Pharma and Biotech Acquisitions
July 7 (Reuters) - Vertex Pharmaceuticals has agreed to buy Crinetics Pharmaceuticals for about $10 billion, expanding its reach beyond blood disorders and pain into rare endocrine diseases.
The move adds to a growing list of high-profile transactions over the past decade by U.S. pharmaceutical companies to acquire promising therapies in fields ranging from oncology and neurology to rare diseases and obesity.
Below are some of the major deals involving U.S.-based pharma and biotech firms from the past decade:
Key Transactions by Year
2026: Recent High-Value Deals
Vertex Pharmaceuticals acquires Crinetics Pharmaceuticals
Year Acquirer Target Deal Description
Value
2026 Vertex Crinetics About $10 To expand its
Pharmaceuticals Pharmaceu billion portfolio in
ticals rare hormonal
diseases
Merck KGaA acquires Bio-Techne
2026 Merck KGaA Bio-Tech $11.3 To expand its
ne billion presence in
the life
sciences
market with
access to
research and
bioprocessing
tools
AbbVie acquires Apogee Therapeutics
2026 AbbVie Apogee $10.9 To expand
Therapeut billion immunology
ics pipeline
GSK acquires Nuvalent
2026 GSK Nuvalent $10.6 To expand
billion late-stage
cancer drug
pipeline
Boston Scientific acquires Penumbra
2026 Boston Penumbra $14.5 To expand
Scientific billion vascular
pipeline
2025: Strategic Expansions
Abbott acquires Exact Sciences
2025 Abbott <ABT.N> Exact up to $23 To gain
Sciences billion access to
Exact
Sciences'
cancer tests,
including
flagship
colorectal
cancer test
Cologuard
Merck acquires Cidara Therapeutics
2025 Merck Cidara $9.2 To gain
Therapeut billion access to
ics Cidara's
experimental
drug for flu
prevention
Pfizer acquires Metsera
2025 Pfizer Metsera $10 To gain a
billion foothold in
the
fast-growing
obesity
treatment
market
Merck & Co acquires Verona Pharma
2025 Merck & Co Verona About $10 Strengthens
Pharma billion Merck's
respiratory
portfolio
amid looming
Keytruda
patent cliff
Johnson & Johnson acquires Intra-Cellular Therapies
2025 Johnson & Intra-Cel $14.6 Expands J&J's
Johnson lular billion footprint in
Therapies brain disease
treatments
2024: Notable Acquisition
Novo Holdings acquires Catalent
2024 Novo Holdings Catalent $16.5 Boosts
billion manufacturing
